about
Biosimilars: potential implications for cliniciansClinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatologyG-CSF and GM-CSF in NeutropeniaExpert perspectives on biosimilar monoclonal antibodies in breast cancerReview article: biosimilars are the next generation of drugs for liver and gastrointestinal diseasesBiosimilars in the United States: Considerations for Oncology Advanced PractitionersBiosimilars of biological drug therapies: regulatory, clinical and commercial considerations.Clinical trial design in biosimilar drug development.Pharmacotherapy of end-stage renal disease.Forecasting drug utilization and expenditure in a metropolitan health region.Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey.Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?Biosimilars: Implications for health-system pharmacists.Formulary Selection Criteria for Biosimilars: Considerations for US Health-System PharmacistsBiosimilar agents in oncology/haematology: from approval to practiceStudy design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.Biosimilar medicines and cost-effectiveness.Biosimilars: current perspectives and future implications.The economic pressures for biosimilar drug use in cancer medicineDoctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs.Expression and biological characterization of an anti-CD20 biosimilar candidate antibody: a case study.Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors.The impact of rheumatoid arthritis and biologics on employers and payers.Comparison of originator and biosimilar therapeutic monoclonal antibodies using comprehensive two-dimensional liquid chromatography coupled with time-of-flight mass spectrometry.Are biosimilars really generics?Erythropoietic stimulating agents.Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body.Transduction of human recombinant proteins into mitochondria as a protein therapeutic approach for mitochondrial disorders.Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors.What do prescribers think of biosimilars?Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments.Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development.Epoetin biosimilars in Europe: five years on.Pharmacovigilance and biosimilars: considerations, needs and challenges.Clinical experience with Zarzio® in Europe: what have we learned?Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantationChronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review.Future directions in inflammatory bowel disease management.Novel products for haemostasis.
P2860
Q26744332-CAABA4F9-2F0D-4538-A4BA-5C73A4D72AB2Q26766028-E4620E04-A40A-4C1D-BEB7-F3FB95FD7FEAQ26800954-9BE13A4E-C321-4225-8FCD-60F36C2CCEAEQ26865410-CCCA5444-135C-4FE7-B2AD-E00CA870FB0DQ27013577-9B1E67B5-6B3D-45B3-9E3F-9805B4B0A341Q27025705-3BC4FD41-9539-4405-8F9E-03340177491AQ30406304-B314B1D1-C225-4F53-BC28-7AC85A6DE734Q30423748-10F7942B-17D9-4A2B-B1F2-163D4CC015DAQ33531889-F5A1E5A2-3EF5-4A5A-AD88-92C6C56B85ACQ33579584-424E6941-EA49-4E5F-8E16-0E598CBC7641Q33673144-838ADA79-5F16-4287-849C-31F1A1FB00C1Q33756369-0500CFE2-FE77-4F39-83DE-FD698FA95F84Q34372394-C23B68DB-712D-4EE3-9AA4-88CF7EF3C44EQ34612781-19050C36-6762-41AD-9691-FC6850F86FA9Q34892411-F1C272DB-F32D-4E53-B8AF-013FA2B64170Q35044368-428970DA-2353-4D1C-A375-5E804EAD3FEBQ35205419-19089072-D7D5-4EBF-8264-EE710235304FQ35732517-FDB553E4-51C0-4535-8D9F-DCCE24054DB8Q35795204-75AA66BD-EC50-47B8-A26B-7B0E55727AD0Q36284094-499DC317-B08E-41A7-BF94-82EF31B5C2D9Q36402809-E162FF7E-8345-460B-9D79-1CF8F90884B1Q36981948-C0D0596F-5471-4699-8E37-B0210998C6B2Q37251489-C8E41E7A-665D-4224-B978-B367877D5FC3Q37327298-4AB3574F-11D3-4FC7-ABDC-64E530A48EDEQ37690328-5F998072-2DAB-4E8E-99EB-5172B8FEC781Q37693160-23A4E5F4-2B26-4F64-B037-27E3DEC6118DQ37700537-87037521-C921-4FE6-9990-2D5BC253B5C8Q37923355-16597842-F489-469F-B6D6-47527087210FQ37931905-5D96E025-FAB9-4887-90AB-B99C2EAEF0EAQ37977012-30AD018E-D7D9-4C50-BB0B-DFC2791ED0FBQ37999380-A4042152-BCD6-4A5E-BFA2-EE4B6FAF31F4Q38006021-AB8D4D7E-3DB1-4211-B1C8-28C9EE05094AQ38046652-5A37D21C-8CB8-416E-B5AC-F51A19BCC8B7Q38067654-B735A037-AF58-4BA7-8A62-9A736ACCADC7Q38092850-2C3ABA4C-201C-4705-82AC-AD445BB6E669Q38125609-D14AF17A-AB3F-4A9E-8C0D-56265BD8A39BQ38186025-FDEABDA5-46A0-42EA-84F7-BE8AE26BAC23Q38201788-808D5182-0A0D-4BA3-AB88-116E937240DAQ38205305-2F552440-8CB4-4B72-AF41-7180AF036C85Q38206850-7108F677-ABDB-43BC-A45D-07854BC8B654
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The challenge of biosimilars.
@en
type
label
The challenge of biosimilars.
@en
prefLabel
The challenge of biosimilars.
@en
P2093
P356
P1433
P1476
The challenge of biosimilars.
@en
P2093
D Niederwieser
H Mellstedt
P304
P356
10.1093/ANNONC/MDM345
P577
2007-09-14T00:00:00Z